The series on “Evidence and Controversies in the treatment of metastatic NSCLC” is edited by Dr. Grace K. Dy, MD, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. This series has included a collection of debate-style brief editorials, featuring back-to-back pro/con position from different clinical experts in the field.
CM227/CM9-LA: evidence supporting ipilimumab-based immunotherapy in the first-line treatment of metastatic NSCLC
Concerns and controversies regarding ipilimumab-based immunotherapy in the first-line treatment of non-small cell lung cancer
Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes
The role of Anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1–49%
Pembrolizumab monotherapy in the first-line treatment of EGFR/ALK wildtype, PD-L1 tumor proportion score (TPS) 1–49%, advanced non-small cell lung cancer (NSCLC): con: “It takes two to tango”
The series “Evidence and Controversies in the treatment of metastatic NSCLC” was commissioned by the editorial office, Precision Cancer Medicine without any sponsorship or funding. Grace K. Dy served as the unpaid Guest Editor for the series.